Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 122

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 122
---
 |     | $               | 109,872 |     |                  |  27,792 |     | $                                      | — |     | $                                                              | — |     | $                      | — |     | $     | 197,664 |
| Robert Hariri MD, Phd (3) |     | $                           |  7,500 |     | $               |       — |     |                  | 131,262 |     | $                                      | — |     | $                                                              | — |     | $                      | — |     | $     | 138,762 |
| Sigmund Rogich            |     | $                           |  8,750 |     | $               | 114,912 |     |                  |  26,484 |     | $                                      | — |     | $                                                              | — |     | $                      | — |     | $     | 150,146 |

| (1) | The aggregate grant date fair value of such awards were computed                                                                             
 in accordance with Financial Accounting Standards Board ASC Topic 718, Stock Compensation (ASC Topic 718), and do not take into account      
 estimated forfeitures related to service-based vesting conditions, if any. The valuation assumptions used in calculating these values        
 are discussed in Note 9 of our Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended June 30, 2024.    
 These amounts do not represent actual amounts paid or to be realized. Amounts shown are not necessarily indicative of values to be achieved, 
 which may be more or less than the amounts shown as awards may subject to time-based vesting.                                                |

| (2) | Mr. Berman passed away in February 2025. |

| (3) | Dr. Hariri resigned from the Board of Directors effective March 
 28, 2025.                                                       |

Our directors are eligible to participate in our equity incentive plans,
which are administered by our Compensation Committee under authority delegated by our Board of Directors. The terms and conditions of
the option grants to our non-employee directors under our equity incentive plans are and will be determined in the discretion of our Compensation
Committee, consistent with the terms of the applicable plan. The fiscal year 2025 annual compensation granted to existing board members
consisted of either an award of RSUs at one unit per share of common stock, a total of 6,690 RSU at a grant date market value of $224